Sansure Biotech Inc. (SHSE:688289) agreed to acquire a 18.63% stake in Shanghai Kehua Bio-Engineering Co.,Ltd (SZSE:002022) from Zhuhai Baolian Asset Management Co., Ltd. for CNY 2 billion on May 12, 2021. Under the terms of the transaction, Sansure Biotech Inc. will acquire 95.86 million shares and shall pay CNY 585 million to the bank account designated by the seller within three working days from the effective date of this agreement (of which, CNY 195 million will serve as the deposit for the transfer of shares. The deposit will be part of the share transfer price after the completion of the transfer of the target shares). On the day when the transfer of the target shares is completed, Sansure Biotech Inc. shall pay CNY 1.4 billion to the bank account designated by the seller. On May 12, 2021, the transaction was approved by the board of directors of Gree Real Estate Co., Ltd., parent of Zhuhai Baolian Asset Management Co., Ltd. at the 18th session of 7th directorate. The transaction was approved by the board of director of Sansure Biotech Inc. the 4th extraordinary meeting of the company's 1st directorate held on May 12, 2021. The transaction is still subject to the shareholders' approval of Sansure Biotech Inc. On May 28, 2021, Sansure Biotech Inc. will hold its 1st special shareholders' meeting for 2021 to review the acquisition of 18.63% stake in the company. On May 28, 2021, the transaction is approved by the shareholders of Sansure Biotech Inc.

Sansure Biotech Inc. (SHSE:688289cancelled the acquisition of 18.63% stake in Shanghai Kehua Bio-Engineering Co.,Ltd (SZSE:002022) from Zhuhai Baolian Asset Management Co., Ltd. on August 5, 2021. The Board of Directors has approved the termination of transaction.